s a healthcare company, Johnson & Johnson understands that climate health affects human health. Research shows that climate change is impacting health in many ways, including changing infectious disease patterns, increasing extreme weather events and heat and the risk of drought and food insecurity. We have taken sustained, long-term action to reduce our greenhouse gas (GHG) emissions, and we encourage our suppliers to do the same. We also work with like-minded partners to advance environmental health equity.
To do our part to help maintain a healthy climate, we’ve set our most ambitious climate goals to date, building on our past achievements while accelerating future actions. Specifically, we are committed to:
Our operational emissions goal has been validated by the Science-Based Targets initiative (SBTi) as being consistent with the reductions required to keep global warming to 1.5°C.
Advancing Renewable Electricity
We are wasting no time making progress towards our renewable electricity goal, because we know there is no time to waste. Today, over 65% of our global electricity use comes from renewable sources. We have built more than 50 on-site renewable energy systems on properties in 20 countries and have executed 15 contracts for off-site renewable electricity procurement. Additionally, we have finalized multiple a deals in the U.S., Canada and Brazil that, when operational, will allow us to source the equivalent of 100% renewable electricity for our operations in these countries.
100% Renewable Electricity in Europe
We are now producing or procuring the equivalent of 100% of our electricity in our European operations* from renewable sources. In total, 12 countries where we have J&J MedTech and Janssen operations are included: Belgium, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Spain, Sweden, Switzerland and the United Kingdom.
This achievement comes thanks to three deals that led to the construction of two new wind farms and one new solar field in Spain, adding to our existing on-site and off-site electricity projects.
*Johnson & Johnson property sites larger than 50,000 ft2 where the company has operational control
Our Renewable Electricity Footprint*
Delivering Energy Efficiency
Through our CO2 Capital Relief Program we allocate up to $40 million per year for energy efficiency programs at our most energy-intensive manufacturing and R&D sites. Each project must show the potential for both emissions reductions and a financial return of at least 15%. Since we started the program in 2005, we’ve completed approximately 270 projects that have helped us avoid around 320,000 metric tons of GHG per year.
Tapping Into New Energy Sources
For decades we have been focused on driving energy efficiency across our operations, but reaching our climate goals will require us to go beyond efficiency projects and renewable electricity. For example, we continue to expand our use of geothermal energy to provide substantial reductions in GHG emissions. At our Janssen campus in Beerse, Belgium multiple wells, each approximately 1.6 miles deep, were completed and will use innovative geothermal energy to help heat and cool buildings across the site. At our Ethicon campus in Cincinnati, Ohio (U.S.), we installed a closed-loop, geothermal system with the capacity to provide heating and cooling to the entire 45-acre campus while substantially reducing emissions.
Engaging Our Suppliers
We know that a collaborative approach is essential to tackle today’s greatest environmental challenges, and we have been working for years with our suppliers to accelerate environmental and social improvements across our value chain. Looking to the future, we have committed to expanding the Johnson & Johnson Supplier Sustainability Program to include all suppliers by 2025. This means there will be even more opportunities for engagement and collaboration on our joint environmental and social priorities.
Collaborating for Greater Impact
In 2021, we joined with 9 other leaders in the pharmaceutical industry to launch Energize, a first-of-its-kind initiative to help decarbonize the global pharmaceutical supply chain. The program aims to educate key industry suppliers on renewable procurement opportunities and help them in their transition to renewable energy. The program has registered hundreds of suppliers on the platform.
In 2022, we announced a new collaboration called Activate, bringing together five pharmaceutical companies to support active pharmaceutical ingredient (API) suppliers in their decarbonization efforts.
For many years, we’ve participated in coalitions that publicly support actions to promote a low carbon economy and mitigate climate change at scale. For example, we work with other companies and organizations through the Clean Energy Buyers Alliance and the Climate Leadership Council to share best practices and encourage the advancement of renewable energy and market-based climate policies. Additionally, we have supported the Paris Climate Agreement through various platforms such as the ‘We Are Still In/America Is All In' campaign, and we were proud to join other companies and investors in signing an open letter to President Biden calling for an ambitious U.S. emissions reduction target. You can read more in our Position on Climate Action.
Click here to read about our work with partners to support solutions for climate change and human health.
Established formal energy management program
Established first enterprise-wide public commitment to reduce CO2 emissions based on Kyoto Protocol
Developed internal CO2 capital relief program, which has resulted in 231 projects and 288,000 metric tons of CO2 saved per year over the past 15 years
Announced goal to reduce CO2 emissions by 20% by 2020 and increase on-site clean energy capacity to 50MW by 2015. Currently over 50 solar arrays and 4 wind turbines built, totaling 56MWs on our properties globally
Supported the UNFCCC Paris Climate agreement and committed to using 100% renewable electricity in our operations by joining RE100. Since then increased our renewable electricity consumption to near 50%
Launched 4th generation science-based climate commitments, accelerating our 100% renewable electricity commitment to 2025, committing to carbon neutrality in our operations and a 20% value chain emissions reduction by 2030
Finalized deals to reach 100% renewable electricity in the U.S., Canada and Europe. Joined Energize with 9 of our peers in the pharmaceutical industry to help increase access to renewable energy within our supply chains.
Announced Activate, a collaboration of pharmaceutical companies to support active pharmaceutical ingredient suppliers. Signed contract for 100% renewable electricity in Brazil.
Cautionary Note Regarding Forward-Looking Statements: This page contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global healthcare reforms; trends toward healthcare cost containment; changes in behavior and spending patterns of purchasers of healthcare products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the healthcare industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the Company’s most recently filed Quarterly Report on Form 10-Q and the Company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made on this page speaks only as of the date presented. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Third-party trademarks used herein are trademarks of their respective owners.